Femasys is trading 10.75% down at $1.78, with no clear company-specific catalyst identified for the October 12 decline. - The October 8 announcement about exhibiting at the ASRM congress concerns a future event and does not establish a reason for the decline. - The broad market was mixed, not sharply lower; available biotech and medical-device context does not establish a sector-wide cause. - Evidence points to an unexplained decline rather than a confirmed news-driven move.